Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition comprising tricyclic compound for prevention or treatment of skin diseases

A technology of cyclic compounds and compositions, applied in skin diseases, drug combinations, metabolic diseases, etc., can solve problems such as no clear disclosure, and achieve the effect of treating or preventing rejection.

Inactive Publication Date: 2004-10-13
FUJISAWA PHARMA CO LTD
View PDF12 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, such dosage forms are not clearly disclosed

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition comprising tricyclic compound for prevention or treatment of skin diseases
  • Pharmaceutical composition comprising tricyclic compound for prevention or treatment of skin diseases
  • Pharmaceutical composition comprising tricyclic compound for prevention or treatment of skin diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0097] FK506 substance

[0098] Dissolve FK506 material with diethylene glycol monoethyl ether. Then 1,3-butanediol and propylene carbonate were added. After visual inspection of complete dissolution of the FK506 substance, carboxyvinyl polymer dispersed in a binary system of isopropyl myristate and diethyl sebacate was added in order to obtain the desired viscosity and a gel for external use. Glue preparation.

Embodiment 2

[0100] According to a method similar to Example 1, the following pharmaceutical compositions 2, 3, 4, 5 and 6 were prepared.

[0101] Composition number

Embodiment 3

[0103] Composition number

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Provided is a pharmaceutical composition comprising a tricyclic compound (I) or its pharmaceutically acceptable salt; monohydric alcohol fatty acid esters; dibasic acid diesters; lower alkylene carbonates; butylene glycol; diethylene glycol mono(lower)alkyl ethers; and thickeners. It is satisfactory in stability and absorption kinetics and / or a low irritation potential.

Description

technical field [0001] The present invention relates to a pharmaceutical composition containing a tricyclic compound which is stable and has very satisfactory absorption kinetics and / or low irritation potential. The composition is useful in the treatment and prevention of various skin diseases. Background technique [0002] Said tricyclic compounds and pharmaceutically acceptable salts thereof used in the present invention are known to have excellent immunosuppressive activity, antimicrobial activity and other pharmacological activities, and thus have therapeutic or prophylactic Value in rejection, graft-versus-host disease, autoimmune diseases and infectious diseases [EP-A-0184162, EP-A-0323042 etc.]. [0003] In detail, the FK506 substance in the tricyclic compound (I) is shown to be useful in the treatment and prevention of transplant rejection in organ transplantation due to its very good immunosuppressive activity. [0004] It is mentioned in EP-A-0315978 that the eth...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07D498/18A61K31/436A61K31/4745A61K47/10A61K47/12A61K47/14A61K47/22A61K47/32A61K47/38A61P1/00A61P1/02A61P1/04A61P3/04A61P3/10A61P9/00A61P9/10A61P11/00A61P11/06A61P13/12A61P17/00A61P17/02A61P17/06A61P17/14A61P19/02A61P21/04A61P25/00A61P25/14A61P25/16A61P25/28A61P27/02A61P29/00A61P31/18A61P35/00A61P37/06
CPCA61K47/14A61K47/12A61K31/436A61K47/10A61K9/0014A61K31/4745A61K47/38A61K47/32A61P1/00A61P1/02A61P1/04A61P11/00A61P11/06A61P13/12A61P17/00A61P17/02A61P17/06A61P17/14A61P19/02A61P21/04A61P25/00A61P25/14A61P25/16A61P25/28A61P27/02A61P29/00A61P3/04A61P31/18A61P35/00A61P37/06A61P9/00A61P9/10A61P3/10C07D405/06
Inventor 上田聪坂井敏郎吉田惠里香
Owner FUJISAWA PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com